CN1626195A - Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method - Google Patents
Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method Download PDFInfo
- Publication number
- CN1626195A CN1626195A CN 200410024546 CN200410024546A CN1626195A CN 1626195 A CN1626195 A CN 1626195A CN 200410024546 CN200410024546 CN 200410024546 CN 200410024546 A CN200410024546 A CN 200410024546A CN 1626195 A CN1626195 A CN 1626195A
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- chinese medicine
- present
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 22
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 241000222336 Ganoderma Species 0.000 claims abstract description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 239000006188 syrup Substances 0.000 claims abstract description 8
- 235000020357 syrup Nutrition 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000208340 Araliaceae Species 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 239000000463 material Substances 0.000 abstract description 4
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 206010013954 Dysphoria Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010040007 Sense of oppression Diseases 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- -1 antiseptic Polymers 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form particles, capsule, tablet, oral liquid, syrup, or dripping pills for treating coronary heart disease and angina pectoris is prepared from 11 Chinese-medicinal materials including ganoderma, ginseng, red sage root, wolfberry fruit, etc. Its advanages is high curative effect.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation, especially treat coronary heart disease, anginal preparation and preparation method thereof, its dosage form comprises tablet, capsule, granule, oral liquid, syrup, drop pill and other dosage forms, belongs to field of traditional Chinese.
Background technology:
Coronary heart disease is a kind of cardiovascular disease of serious harm human body health, is commonly encountered diseases, frequently-occurring disease clinically.China's Statistical Beijing City coronary heart disease death rate in 1973 is to rise to 62.0/10 ten thousand people in 21.7/10 ten thousand, 1986; Shanghai coronary heart disease death rate in 1974 be 15.7/10 ten thousand, 1984 be 37.4/10 ten thousand people.This shows that the coronary heart disease death rate is growth trend year by year.Therefore be important problem in the medical domain with Chinese medicine to the treatment research and the Prevention Research of coronary heart disease.The Chinese medicine angina pectoris has long history and rich experience.Advantages such as the effectiveness of the organic conception of the traditional Chinese medical science, determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, dynamic equilibrium and Chinese medicine treatment primary disease, innocuousness, persistence, multiformity are suitable for complicated and diversified coronary heart disease treatment.Taking Chinese medicine for a long time can reside and prevent integrating prevention, treatment, rehabilitation in controlling.Therefore, effective prescription of development treatment coronary heart disease has important theoretical meaning and use value.
The present invention is just at angina pectoris, and card belongs to deficiency of both QI and blood, and malaise person and establishing has nourishing qi and blood, and the effect of tranquilizing by nourishing the heart can be used for cardiopalmus, palpitation with a distress feeling, soreness of waist and knee, insomnia forgetfulness.The neurasthenia there is the auxiliary treatment effect.By clinical observation, the present invention is to angina pectoris total effective rate 96%, and the electrocardiogram total effective rate is 52.00%, and does not find untoward reaction, and clinical effectiveness is satisfied.At present, clinical in evident in efficacy, safety is good, and Chinese medicine preparation easy to use is still for being badly in need of.By clinical experiment, we think that curative effect of the present invention is reliable, and have one's own knack on prescription medicine, focus on benefiting vital QI and blood, reach the purpose that nourishes heart by calming the nerves.Therefore, exploitation of the present invention is expected to be expected to obtain better economic, social benefit after applying for a clinical safety, the desirable Chinese medicine preparation effective, cheap, easy to use of providing.
Summary of the invention:
The invention belongs to a kind of Chinese medicine preparation for the treatment of angina pectoris, it is characterized in that forming, comprise Ganoderma 10～80%, Radix Ginseng 1～10%, Radix Salviae Miltiorrhizae 3～20%, the Cortex Eucommiae 2～18%, Fructus Lycii 1.2～15%, Radix Polygoni Multiflori Preparata 1.5～18%, Semen Ziziphi Spinosae 1.5～15%, Fructus Schisandrae Chinensis 1～16%, Radix Rehmanniae Preparata 1～19%, Radix Angelicae Sinensis 1.5～18%, Mel 1～60% by the Chinese prescription of nourishing qi and blood, tranquilizing by nourishing the heart.
Technical scheme of the present invention is: the Chinese medicine of respectively distinguishing the flavor of among the present invention is extracted, and the extracting solution concentrating under reduced pressure becomes concentrated solution; After concentrated solution is dried to extract dry powder by distinct methods,, can be made into solid preparations such as granule, capsule, tablet by adding different auxiliary material respectively; Also can in concentrated solution, add an amount of distilled water, after water precipitating filters, add adjuvant and antiseptic and make liquid preparations such as oral liquid and syrup.Add different auxiliary material in the different dosage form of the present invention, do not influence clinical effectiveness of the present invention, these adjuvants comprise starch, microcrystalline Cellulose, magnesium stearate, dextrin, lactose, sucrose, antiseptic, Polyethylene Glycol etc.The present invention can satisfy the requirement of vast angina pectoris patient to different dosage form.
The purpose of this invention is to provide a kind of Chinese medicine preparation that angina pectoris has obvious curative effects for the treatment of.The main pharmacodynamics experimental result of this preparation shows: this preparation can significantly reduce myocardial oxygen consumption; Rat heart muscle ischemia effect due to antagonism isoproterenol and the pituitrin; Reduce the incidence rate of chloroform induced mice ventricular fibrillation, prolong the pentobarbital sodium mouse sleep time.Acute toxicity test of the present invention and long term toxicity test result show and do not see overt toxicity reaction.
Clinically with oral liquid treatment deficiency of both QI and blood of the present invention, malaise card patient 150 examples.The result shows: to the angina pectoris curative effect, produce effects 60 examples (40%), effective 84 examples (56.00%), total effective rate 96.00%, most of patient 12 days left and right sides angina pectoris attacks number of times of taking medicine are gradually reduced to disappearance, pain character also obviously alleviates before the treatment, and the electrocardiogram total effective rate is 52.00%.To improving the significant curative effect that moved down of ischemic ST.Better for symptom curative effects such as the ambition dull pain of improving the patient, sensation of oppression over the chest with shortness of breath, palpitation and night sweat, dysphoria and insomnia, soreness of the waist and knees, tinnitus dizzinesses.Do not see obvious adverse reaction in the clinical research process, illustrate that the present invention takes safety.
Traditional Chinese medical science efficacy analysis of the present invention:
1 materials and methods
1.1 outpatient's 94 examples are observed in this clinical trial of physical data altogether, inpatient's 56 examples, male 95 examples, women 55 examples, Affiliated Hospital of Qingdao Medical Inst 90 examples wherein, Shandong 418 hospitals 60 examples.
1.2 Therapeutic Method is taken oral liquid of the present invention, each 10ml.Every day 2 times (sooner or later respectively once), (medicine) being taken before meal, 30 days is a course of treatment.About 10 days at interval, take second course of treatment, take medicine altogether three courses of treatment.
1.3 observation item is observed curative effect to treat angina pectoris, ECG curative effect, traditional Chinese medical science disease curative effect (ambition dull pain, sensation of oppression over the chest with shortness of breath, cardiopalmus, night sweat, dysphoria and insomnia, soreness of the waist and knees, tinnitus, dizziness, red tongue or with purplish patch, thready and rapid pulse) before and after the treatment.
2 results
(1) curative effect to treat angina pectoris
Table 1-1 curative effect to treat angina pectoris is (routine %) relatively
The example digital display is imitated enabledisable and is increased the weight of total effective rate
Treatment organizes 150 60 84 60 96.00%
(40.00％) (56.00％) (4.00％)
Table 2-2 angina pectoris onset, extinction time and analysis (day X ± S)
Example number angina pectoris onset angina pectoris disappears
Time (my god) time (my god)
Treatment organizes 150 9.14 ± 3.68 19.93 ± 4.54
(2) ECG curative effect
Table 2-1 ECG curative effect relatively
The produce effects enabledisable increases the weight of total effective rate
Example % example % example % example %
Treatment organizes 33 45 72 0 52.00%
(22.00％) (30.00％) (48.00％)
(3) tcm syndrome is treated
Table 3-1 tcm syndrome curative effect (routine %)
The control of example clinic control produce effects enabledisable total effective rate shows rate
n ％ n ％ n ％ n ％ ％ ％
The smelting treatment organizes 150 24 16.00% 51 34.00% 69 46.00% 6 4.00% 96.00% 50.00%
The every tcm syndrome improvement of table 3-2 situation relatively
Treatment group (n=50)
Syndrome
(n) treatment back (n) disappearance rate (%) before the treatment
Ambition dull pain 150 61 59.33
Sensation of oppression over the chest with shortness of breath 150 87 42.00
Cardiopalmus 141 45 68.09
Night sweat 117 63 46.15
Dysphoria and insomnia 90 24 73.33
Soreness of the waist and knees 93 55 40.86
Tinnitus 63 37 41.27
Dizzy 72 27 62.5
Red tongue or with purplish patch 126 52 58.73
Thready and rapid pulse 123 60 51.22
By table 1～3 as can be known, the present invention is to the angina pectoris curative effect, produce effects 60 (40%), effective 84 (56.00%), total effective rate 96.00%, most of patient 12 days left and right sides angina pectoris attacks number of times of taking medicine are gradually reduced to disappearance, and pain character also obviously alleviates before the treatment, and the electrocardiogram total effective rate is 52.00%.To improving the significant curative effect that moved down of ischemic ST.Better for symptom curative effects such as the ambition dull pain of improving the patient, sensation of oppression over the chest with shortness of breath, palpitation and night sweat, dysphoria and insomnia, soreness of the waist and knees, tinnitus dizzinesses.
Prescription of the present invention can also add the Chinese medicine that other have nourishing qi and blood, tranquilizing by nourishing the heart on the basis of above-mentioned 11 flavor medicines.
Using method of the present invention: oral, every day 2 times.Each 1～2 oral liquid (or 10～20ml syrup, or 10 of drop pill, or 2～4 capsules, or 2～4 tablets of tablets, or one bag of granule).30 days is a course of treatment.
The specific embodiment:
Embodiment 1:
Get Ganoderma 600g, Radix Salviae Miltiorrhizae 25g, Cortex Eucommiae 25g, Fructus Lycii 25g, Radix Polygoni Multiflori Preparata 15g, Semen Ziziphi Spinosae (stir-fry) 15g, Fructus Schisandrae Chinensis 15g, Radix Rehmanniae Preparata 15g, Radix Angelicae Sinensis 30g and add 70% alcohol reflux 3 times, each 2 hours, merge extractive liquid,, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.16～1.18 (50 ℃); Get Radix Ginseng 10g again and be ground into coarse powder, 60% ethanol percolate extraction 2 times merges percolate, reclaims ethanol, and being condensed into relative density is the concentrated solution of 1.20～1.22 (50 ℃); Get above-mentioned two kinds of concentrated solutions and merge, being condensed into relative density is the thick paste of 1.20～1.23 (50 ℃), adds Mel 50g, mixing, and drying is pulverized the dried medicated powder of extraction very of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 300ml distilled water and make dissolving, cold putting (2～2 ℃) 24 hours filters, and adds Mel 600g, mixing, filtrate is extraction medicinal liquid of the present invention.
Embodiment 2:
Get Ganoderma 250g, Radix Salviae Miltiorrhizae 80g, the Cortex Eucommiae 50, Fructus Lycii 40g, Radix Polygoni Multiflori Preparata 40g, Semen Ziziphi Spinosae (stir-fry) 30g, Fructus Schisandrae Chinensis 20g, Radix Rehmanniae Preparata 30g, Radix Angelicae Sinensis 15g adds 40% alcohol reflux 3 times, each 2 hours, merge extractive liquid,, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.18～1.20 (50 ℃); Get Radix Ginseng 15g again and be ground into coarse powder, 40% ethanol percolate extraction 2 times merges percolate, reclaims ethanol, and being condensed into relative density is the concentrated solution of 1.18～1.20 (50 ℃); Get above-mentioned two kinds of concentrated solutions and merge, being condensed into relative density is the thick paste of 1.20～1.23 (50 ℃), adds Mel 30g, mixing, and drying is pulverized the dried medicated powder of extraction very of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 200ml distilled water and make dissolving, cold putting (2～2 ℃) 24 hours filters, and adds Mel 400g, mixing, filtrate is extraction medicinal liquid of the present invention.
Embodiment 3:
Get Ganoderma 400g, Radix Salviae Miltiorrhizae 20g, Cortex Eucommiae 20g, Fructus Lycii 15g, Radix Polygoni Multiflori Preparata 15g, Semen Ziziphi Spinosae (stir-fry) 15g, Fructus Schisandrae Chinensis 10g, Radix Rehmanniae Preparata 10g, Radix Angelicae Sinensis 10g and add 60% alcohol reflux 2 times, each 3 hours, merge extractive liquid,, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.18～1.20 (50 ℃); Get Radix Ginseng 20g again and be ground into coarse powder, 50% alcohol reflux 2 times, each 2 hours, merging filtrate reclaimed ethanol, and being condensed into relative density is the concentrated solution of 1.20～L 22 (50 ℃); Get above-mentioned two kinds of concentrated solutions and merge, being condensed into relative density is the thick paste of 1.20～1.23 (50 ℃), adds Mel 20g, mixing, and drying is pulverized the dried medicated powder of extraction very of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 200ml distilled water and make dissolving, cold putting (2～2 ℃) 24 hours filters, and adds Mel 300g, mixing, filtrate is extraction medicinal liquid of the present invention.
Embodiment 4:
Get Ganoderma 550g, Radix Ginseng 35g, Radix Salviae Miltiorrhizae 40g, Cortex Eucommiae 25g, Fructus Lycii 20g, Radix Polygoni Multiflori Preparata 15g, Semen Ziziphi Spinosae (stir-fry) 20g, Fructus Schisandrae Chinensis 15g, Radix Rehmanniae Preparata 30g, Radix Angelicae Sinensis 25g adds 50% alcohol reflux 3 times, each 2 hours, merge extractive liquid,, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.18～1.20 (50 ℃); Being condensed into relative density is the thick paste of 1.20～1.23 (50 ℃), adds Mel 30g, mixing, and drying is pulverized the dried medicated powder of extraction very of the present invention; Or get above-mentioned concentrated solution, and adding the 300ml distilled water and make dissolving, cold putting (2～2 ℃) 24 hours filters, and adds Mel 100g, mixing, filtrate is extraction medicinal liquid of the present invention.
Embodiment 5: syrup
Will be in the foregoing description any one extracts and adds 0.3% sodium benzoate in the medicinal liquid, adds sucrose 300g, xanthan gum 100g, makes the 1000ml syrup, syrup of the present invention.
Embodiment 6: oral liquid
Will be in the foregoing description any one extracts and adds 0.3% sodium benzoate in the medicinal liquid, the 500ml distilled water, sterilization, the 1000ml oral liquid is made in fill, oral liquid of the present invention.
Embodiment 7: granule
Will be in the foregoing description any one extracts and adds lactose 200g in the dried medicated powder, and dextrin 600g granulates, and granulate sieves, and makes the 1000g granule, granule of the present invention.
Embodiment 8: capsule
Will be in the foregoing description any one extracts and adds starch 125g in the dried medicated powder, mixes, and granulates, and sieves, and makes 1000 capsules, capsule of the present invention.
Embodiment 9: tablet
Will be in the foregoing description any one extracts and adds starch 150g in the dried medicated powder, mixes, granulate, oven dry, granulate sieves, and adds microcrystalline Cellulose 20g, magnesium stearate 2g, mixing is pressed into 1000, tablet of the present invention.
Embodiment 10: drop pill
To any one extract in the dried medicated powder in the foregoing description,, add and be heated to stirring and dissolving among fused Polyethylene Glycol-6000 800g, drip and make 1000 balls, drop pill of the present invention.
According to prescription of the present invention, can also make the preparation of other dosage forms such as suspensoid.
Claims (3)
1. a Chinese medicine preparation for the treatment of angina pectoris is characterized in that described Chinese medicine preparation is to be prepared from by comprising that the following dosage proportion raw material is extracted: Ganoderma 10～80%, Radix Ginseng 1～10%, Radix Salviae Miltiorrhizae 3～20%, the Cortex Eucommiae 2～18%, Fructus Lycii 1.2～15%, Radix Polygoni Multiflori Preparata 1.5～18%, Semen Ziziphi Spinosae 1.5～15%, Fructus Schisandrae Chinensis 1～16%, Radix Rehmanniae Preparata 1～19%, Radix Angelicae Sinensis 1.5～18%, Mel 1～60%.
2. the preparation method of the Chinese medicine preparation of the described treatment angina pectoris of claim 1, the technological process that it is characterized in that described preparation is: get Ganoderma, Radix Ginseng, Radix Salviae Miltiorrhizae, the Cortex Eucommiae, Fructus Lycii, Radix Polygoni Multiflori Preparata, Semen Ziziphi Spinosae, Fructus Schisandrae Chinensis, Radix Rehmanniae Preparata, Radix Angelicae Sinensis and add 40～70% ethanol extraction 2～3 times, merge extractive liquid,, filter, reclaim ethanol, be condensed into relative density and be 1.16～1.25 concentrated solution, add Mel, mixing, available distinct methods drying, pulverize, be the dried medicated powder of extraction of the present invention; Or get above-mentioned concentrated solution and add 200～500ml distilled water and make dissolving, cold putting 24 hours filters, and adds Mel, mixing, and filtrate is the present invention and extracts medicinal liquid.
3. the described Chinese medicine preparation of claim 1, it is characterized in that can be made into granule, capsule, tablet, oral liquid, syrup, drop pill by adding starch, dextrin, microcrystalline Cellulose, magnesium stearate, lactose, sucrose, xanthan gum, Polyethylene Glycol adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410024546 CN1264547C (en) | 2004-08-11 | 2004-08-11 | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410024546 CN1264547C (en) | 2004-08-11 | 2004-08-11 | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1626195A true CN1626195A (en) | 2005-06-15 |
| CN1264547C CN1264547C (en) | 2006-07-19 |
Family
ID=34763365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410024546 Expired - Lifetime CN1264547C (en) | 2004-08-11 | 2004-08-11 | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1264547C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843758B (en) * | 2009-12-09 | 2011-12-21 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating coronary disease |
| CN105267690A (en) * | 2015-03-17 | 2016-01-27 | 孔冬梅 | Traditional Chinese medicine for treating angina pectoris |
| CN106361889A (en) * | 2016-08-31 | 2017-02-01 | 单晓春 | Heart nourishing and kidney regulating granule, preparation method thereof and application of particle |
| CN107714849A (en) * | 2017-11-16 | 2018-02-23 | 广西博白县华春福家庭农场 | A kind of Chinese medicine composition for treating myocardial ischemia and preparation method thereof |
-
2004
- 2004-08-11 CN CN 200410024546 patent/CN1264547C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843758B (en) * | 2009-12-09 | 2011-12-21 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating coronary disease |
| CN105267690A (en) * | 2015-03-17 | 2016-01-27 | 孔冬梅 | Traditional Chinese medicine for treating angina pectoris |
| CN106361889A (en) * | 2016-08-31 | 2017-02-01 | 单晓春 | Heart nourishing and kidney regulating granule, preparation method thereof and application of particle |
| CN106361889B (en) * | 2016-08-31 | 2019-10-22 | 单晓春 | Nourishing heart tune kidney particle and its preparation method and application |
| CN107714849A (en) * | 2017-11-16 | 2018-02-23 | 广西博白县华春福家庭农场 | A kind of Chinese medicine composition for treating myocardial ischemia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1264547C (en) | 2006-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038745B (en) | Hypolipidemic traditional Chinese medicine | |
| CN1112836A (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN1302796C (en) | Traditional Chinese medicament for treating woman subhealthy faligue syndrome and its preparation method | |
| CN1264547C (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN1189203C (en) | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN101249158B (en) | Traditional Chinese medicine preparation for preventing and treating cardiovascular and cerebrovascular diseases and preparation | |
| CN1440804A (en) | Antilipemic Chinese medicine | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN107596008B (en) | Preparation method of Gushukang preparation | |
| CN101455813A (en) | Traditional Chinese medicine preparation capable of improving memory and treating amnesia and preparation method thereof | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN1927366A (en) | Traditional Chinese medicine composition for treating chronic enterogastritis | |
| CN1672722A (en) | Heart-nourishing and tranquilizing medicine and its prepn process | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN108295040A (en) | Yuxintong capsules preparation method | |
| CN1911275A (en) | Traditional Chinese medicine composition used for treating brain apoplexia sequela | |
| CN101104033A (en) | Traditional Chinese medicinal preparation for treating Parkinson's disease and preparing process thereof | |
| CN1127968C (en) | Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method | |
| CN1284551C (en) | Chinese medicinal preparation and preparing method for acute cerebral infarction | |
| CN1091382C (en) | Compound Lingxian headache-treating capsule and its preparation | |
| CN1733107A (en) | Medicine for treating coronary disease and apoplexy sequelae and process for preparing the same | |
| CN104825784A (en) | Traditional Chinese medicine composition with anti-gastric cancer activity and preparation method and application of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG C.P. FREDA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LING PEIXUE Effective date: 20091225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Lunan Road, hi tech Zone, Shandong, Ji'nan Patentee after: Shandong Mingren Furuida Pharmaceutical Co.,Ltd. Address before: No. 264 mountain road, Lixia District, Shandong, Ji'nan Patentee before: Ling Peixue |
|
| C53 | Correction of patent of invention or patent application | ||
| C56 | Change in the name or address of the patentee | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ling Peixue Inventor after: Zhang Ling Inventor after: Pang Xiaoyang Inventor after: Cui Yan Inventor before: Ling Peixue Inventor before: Zhang Ling Inventor before: Jing Rui Inventor before: Wang Huan Inventor before: Qu Yanwei Inventor before: Pang Xiaoyang Inventor before: Cui Yan |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LING PEIXUE ZHANG LING JING RUI WANG HUAN QU YANWEI PANG XIAOYANG CUI YAN TO: LING PEIXUE ZHANG LING PANG XIAOYANG CUI YAN |
|
| CP03 | Change of name, title or address |
Address after: Hi tech District Ji'nan city Shandong province 250104 Road No. 3333 Patentee after: SHANDONG MINGREN FURUIDA PHARMACEUTICAL Co.,Ltd. Address before: 250104 Lunan Road, Ji'nan hi tech Zone, Shandong Patentee before: Shandong Mingren Furuida Pharmaceutical Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060719 |